ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 839

Disease Activity, Cytokine Profiles, and the Risk of Incident Diabetes in Rheumatoid Arthritis

Joshua Baker1, Bryant England 2, Michael George 3, Grant Cannon 4 and Ted Mikuls 5, 1University of Pennsylvania, Philadelphia, PA, 2VA Nebraska-Western IA Health Care System & University of Nebraska Medical Center, Omaha, 3University of Pennsylvania, Philadelphia, 4Salt Lake City VA Medical Center and Univeristy of Utah, Salt Lake City, UT, 5VA Nebraska-Western IA Health Care System & University of Nebraska Medical Center, Omaha, NE

Meeting: 2019 ACR/ARP Annual Meeting

Keywords: Diabetes, Disease Activity and obesity, Rheumatoid arthritis (RA)

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print
Session Information

Date: Sunday, November 10, 2019

Title: 3S078: RA – Diagnosis, Manifestations, & Outcomes I: Pulmonary & Other Comorbidities (839–844)

Session Type: ACR Abstract Session

Session Time: 2:30PM-4:00PM

Background/Purpose: Rheumatoid arthritis is associated with a higher risk of diabetes mellitus (DM) and cardiovascular disease. While disproportional obesity and visceral fat accumulation may contribute to a higher incidence of DM, the systemic inflammatory disease may directly lead to insulin resistance and promote the development of cardiometabolic disease. Our aim was to evaluate associations between disease activity (including evaluation of specific cytokines and chemokines) among veterans with RA and determine independent associations with incident DM incidence in a longitudinal cohort.

Methods: Participants were enrollees in a multicenter, longitudinal observational cohort of US veterans with RA. Baseline demographics, comorbidities, body mass index (BMI), ACPA status, disease activity (DAS28-CRP), and active therapies were derived from query of the electronic medical record and registry data. Therapies and disease activity were assessed as time-varying covariates in initial models. Seventeen cytokines and chemokines were measured in banked serum obtained at the time of enrollment in a subset of partiipants using a bead-based multiplex assay. Cytokine/chemokine values were log-adjusted and standardized (all values are per 1 SD). Incident DM was defined as the presence of a new diagnosis code at any time in follow-up (following at least 12 months of follow up without a code).  Multivariable Cox proportional hazards models evaluated associations between clinical factors and incident DM. Independent associations between specific cytokines and chemokines were assessed adjusting for age, sex, race, smoking, and medication use at baseline.

Results: Among 1,918 RA patients without prevalent DM, there were 239 cases of incident DM over 9,055 person-years of follow-up. Patients with high disease activity, obese BMI, older age, male sex, and non-white race were at the greatest risk for incident DM (Table 1). Those using TNFi were at significantly lower risk. In models adjusting for demographics, smoking, and baseline medication use, two chemokines evaluated were significantly associated with the incidence of DM (per 1 SD). These were Macrophage Inhibitory Protein (MIP)-1b [HR 1.20 (95% CI 1.04, 1.39) p=0.01] and Interleukin(IL)-8 [HR 1.16 (95% CI 1.02, 1.33) p=0.02] (Figure). Higher quartiles of MIP-1b and IL-8 were associated with incident DM in a dose-dependent manner (Table 2). These associations were not attenuated with adjustment for DAS28-CRP.

Conclusion: Older age, male sex, higher disease activity, greater BMI, and elevated levels of the chemokines MIP-1b and IL-8 are associated with incident DM in veterans with RA.  Notably, levels of IL-1, TNF-a, and IL-6 were not significantly associated with incident DM in this population although TNFi use was predictive of future DM. Future study may help to determine if other targeted treatments in at-risk individuals could help to prevent the development of DM in patients with RA.


cytkines and DM_Table 1

Table 1: Association between clinical factors and the risk of incident diabetes. Disease activity and medications evaluated as time-varying covariates.


cytokines and DM_Table 2

Table 2: Cox proportional hazards models assessing associations between quartile of MIP-1 and IL-8 and incident diabetes -2 separate models-.


MIP-1 IL8 graph

Figure: Hazard ratios for the risk of incident diabetes among rheumatoid arthritis patients by individual cytokine concentrations -per 1 SD- adjusting for age, sex, race, current smoking, baseline body mass index, and baseline medication use -each represents a separate model-.


Disclosure: J. Baker, Bristol-Myers Squib, 5, Burns-White LLC, 5, Myriad RBM, 2; B. England, None; M. George, AbbVie, 5, Bristol Myers Squibb, 2, Bristol-Myers Squibb, 2; G. Cannon, Amgen, 2; T. Mikuls, BMS, 2, Horizon, 2.

To cite this abstract in AMA style:

Baker J, England B, George M, Cannon G, Mikuls T. Disease Activity, Cytokine Profiles, and the Risk of Incident Diabetes in Rheumatoid Arthritis [abstract]. Arthritis Rheumatol. 2019; 71 (suppl 10). https://acrabstracts.org/abstract/disease-activity-cytokine-profiles-and-the-risk-of-incident-diabetes-in-rheumatoid-arthritis/. Accessed .
  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

« Back to 2019 ACR/ARP Annual Meeting

ACR Meeting Abstracts - https://acrabstracts.org/abstract/disease-activity-cytokine-profiles-and-the-risk-of-incident-diabetes-in-rheumatoid-arthritis/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology